Institut Catala De Retina S.L.
- Address
- lock Available on a paid plan
Eye Diseases
At Institut Catala De Retina S.L., the Clinical Trial Unit is running studies focused on a wide range of eye diseases, especially age-related macular degeneration, geographic atrophy, diabetic macular edema, and thyroid eye disease. These trials are designed to test new treatments, compare them with current standards, and better understand how to preserve vision in people with progressive retinal and corneal conditions.
- Research on diabetic macular edema and macular neovascularization to improve vision outcomes
- Studies in neovascular and dry age-related macular degeneration aimed at slowing disease progression
- Trials for geographic atrophy and related forms of retinal degeneration to assess new therapies
- Comparative studies in polypoidal choroidal vasculopathy and other retinal vascular disorders
Overall, the site is contributing to clinical research that seeks to improve treatment effectiveness, protect visual function, and expand options for patients with chronic retinal disease.
Ocular Physiological Phenomena
The research program also includes work on ocular physiological phenomena, with attention to how the eye responds to treatment in conditions such as Fuchs endothelial corneal dystrophy and thyroid eye disease. These studies explore both symptom control and functional recovery, helping to evaluate whether new approaches can improve everyday vision and eye health.
- Studies of Fuchs endothelial corneal dystrophy focused on corneal recovery and visual improvement
- Trials in thyroid eye disease assessing new options for inflammation and disease control
- Research on visual function changes after treatment in corneal and orbital disorders
- Clinical evaluation of therapies intended to support ocular healing and functional restoration
This area reflects a broader effort to understand eye function beyond the retina, supporting innovation in both diagnosis and treatment for complex ophthalmic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Eyebiotech Limited1active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eyebiotech Limited3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut Catala De Retina S.L.
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12 Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy | Kowa Research Institute Inc. | Phase III | Not Recruiting | Aug 2023 | Oct 2025 |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 3 | Unknown | 2021-08-27 | 2026-06-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.